title: Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
abstract: OBJECTIVE
  Is treatment with factor Xa inhibitors associated with better efficacy and safety compared with the vitamin K antagonist warfarin for preventing strokes or other systemic embolic events in patients with atrial fibrillation?
  
  
  CONCLUSIONS
  Compared with warfarin, factor Xa inhibitors are associated with a lower risk of stroke and other systemic embolic events in patients with atrial fibrillation. Factor Xa inhibitors were associated with lower rates of intracranial hemorrhage and mortality compared with warfarin. Factor Xa inhibitors were associated with a reduction in major bleeding events, but there was heterogeneity between the included studies, and the reduction was not statistically significant in a prespecified sensitivity analysis.
authors.affiliation: Department of Internal Medicine, Oslo University Hospital, Oslo, Norway.
authors.forename: Karsten M H
authors.initials: KM
authors.lastname: Bruins Slot
authors.affiliation: Department of Internal Medicine, Oslo University Hospital, Oslo, Norway.
authors.forename: Eivind
authors.initials: E
authors.lastname: Berge
mesh_terms: D001281:Atrial Fibrillation / Q000150:complications*; D004617:Embolism / Q000517:prevention & control*; D065427:Factor Xa Inhibitors; D006801:Humans; D020766:Intracranial Embolism / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D065427:Factor Xa Inhibitors; D014812:Vitamin K